Xuan Ding, M.D., Ph.D.

  1. Geriatrician
  1. Aburub A, Sperry DC, Bhattachar S, Lobo E, Ding X, Rose JP. Relative Bioavailability Risk Assessment: A Systematic Approach to Assessing In Vivo Risk Associated With CM&C-Related Changes. J Pharm Sci. 2019 Jan; 108 (1):8-17 Epub 2018 July 25
    View PubMed
  2. Ding X, Day JS, Sperry DC. Physiologically Based Absorption Modeling to Design Extended-Release Clinical Products for an Ester Prodrug. AAPS J. 2016 Nov; 18 (6):1424-1438 Epub 2016 July 12
    View PubMed
  3. Ding X, Gueorguieva I, Wesley JA, Burns LJ, Coutant CA. Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling. AAPS J. 2015 Nov; 17 (6):1395-406 Epub 2015 July 01
    View PubMed
  4. Ding X, He M, Kulkarni R, Patel N, Zhang X. Investigation of clinical pharmacokinetic variability of an opioid antagonist through physiologically based absorption modeling. J Pharm Sci. 2013 Aug; 102 (8):2859-74 Epub 2013 June 11
    View PubMed
  5. Ding X, Rose JP, Van Gelder J. Developability assessment of clinical drug products with maximum absorbable doses. Int J Pharm. 2012 May 10; 427 (2):260-9 Epub 2012 Feb 13
    View PubMed
  6. Ding X, Rath P, Angelo R, Stringfellow T, Flanders E, Dinh S, Gomez-Orellana I, Robinson JR. Oral absorption enhancement of cromolyn sodium through noncovalent complexation. Pharm Res. 2004 Dec; 21 (12):2196-206
    View PubMed
  7. Ding X, Stringfellow TC, Robinson JR. Self-association of cromolyn sodium in aqueous solution characterized by nuclear magnetic resonance spectroscopy. J Pharm Sci. 2004 May; 93 (5):1351-8
    View PubMed